Results show dosing intervals increasing by two weeks or longer for patients with diabetic macular edema and neovascular (wet) age-related macular degeneration who switch to Eylea HD.

In a study in mice, a wireless implant was able to release glucagon as an emergency treatment for hypoglycemia, a serious ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Anti-VEGF and anti-complement therapies work on distinct mechanisms in age-related macular degeneration, and both may be required to treat patients with advanced disease or complex cases.

Data shared by Schneider showed that 45% of those originally assigned to the Eylea HD groups had completed dosing intervals of 20 weeks or more. At the end of the 156-week trial, 28% had an assigned ...

New insights emerge from ongoing analyses of GA studies, enhancing AMD treatment strategies and patient management at Bay Area Retina Associates.

Discover new safety insights on Syfovre for geographic atrophy treatment, as Roger A. Goldberg highlights promising long-term data at ASRS 2025.

New findings reveal Syfovre may protect central vision in macular degeneration patients, delaying vision loss and enhancing treatment strategies.

More than 60 companies pledged to improve healthcare technology during a White House “Make Health Tech Great Again” event hosted as part of the Centers for Medicare & Medicaid Services Health Tech ...

New findings reveal that early treatment with Syfovre significantly improves vision preservation in geographic atrophy ...

Cigna has sold its Medicare businesses and slashed the number of people it covers in its ACA plans by more than half.

CVS Health reports Q2 earnings decline due to litigation charges but boost adjusted EPS guidance, highlighting transformation ...